More recently, the use of monoclonal antibodies such as anti-IgE, anti-IL-5, anti-IL-5R, and anti-IL-4/IL-13Rα has been demonstrated to be able to control asthma pathogenesis and hence symptoms, but not to resolve the disease. Here, IL4 is linked to asthma.